ANAlireza Norouzi

Alireza Norouzi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alireza Norouzi has a total of 156 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Insights into Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: The Role of Fibrinogen and Pepsinogen

    by Zahra Eslami, Alireza Norouzi

    Background: Fibrinogen is a multifunctional protein that contributes to inflammatory processes. Elevated levels of fibrinogen have been associated with increased liver fibrosis and disease severity of non-alcoholic steatohepatitis (NASH). Fibrinogen appears to interact with other factors implicated in NASH pathophysiology, such as activation of immune cells to induce pro-inflammatory cytokines and cellular signaling pathways. Additionally, fibrinogen-mediated pathways may disrupt normal tissue repair processes. Pepsinogen, the inactive precursor of pepsin and a specific functional enzyme in the gastric mucosa, is a serological marker with subtypes closely related to different gastrointestinal diseases. Changes in pepsinogen levels in liver disease are not entirely understood and likely relate to many factors, including inflammation, altered gastrin levels, and Helicobacter pylori infection. The clinical implications of altered pepsinogen levels in liver disease are still under investigation, but they may have relevance in the diagnosis and monitoring of liver disease. Methods: Databases searched included PubMed, Google Scholar, and Scopus from 2005 to 2024, and the following keywords were used: fibrinogen, pepsinogen, non-alcoholic steatohepatitis, NASH, non-alcoholic fatty liver disease, NAFLD, and fibrosis. Results: As a potential biomarker for NASH, measuring fibrinogen levels could offer valuable insights into disease diagnosis and progression monitoring. On the other hand, pepsinogen is involved in gut health and liver function, contributing to liver inflammation and fibrosis through mechanisms like the gut-liver axis and signaling pathways. Conclusion: Overall, both fibrinogen and pepsinogen appear to have a more significant negative impact on liver health and the progression of NAFLD than beneficial effects. Integrating assessments of fibrinogen and pepsinogen into clinical practice could facilitate earlier intervention strategies aimed at slowing disease progression.

  • Open Access

    Comparing Two Treatment Regimens for Helicobacter pylori Eradication: Furazolidone or Clarithromycin?

    by Shirin Rezaei, Abdollah Pooshani, Sima Besharat, Mehrangiz Pichak, Alireza Norouzi

    Background and Objective: Clarithromycin-based quadruple treatment is a common treatment regimen for Helicobacter pylori (H. pylori) eradication in Iran. However, its success rate has been unsatisfactory in recent years due to increasing antibiotic resistance. This study aimed to compare the two treatment regimens, i.e., furazolidone and clarithromycin, for H. pylori eradication. ...

  • Correlation Between Different Shapes of Major Papilla With Outcomes of Endoscopic Retrograde Cholangiopancreatography in a Prospective Study

    by Amirhossein Fahimi, Alale Langari, Gholamreza Roshandel, Fatemeh Hasani, Mohammad Ebrahim Kherad, Fatemeh Aghaei, Alireza Norouzi

    Introduction: Several factors affect the difficulty, clinical success, and side effects related to endoscopic retrograde cholangiopancreatography (ERCP), of which the endoscopic appearance of the major papilla is one of the most important. This study aimed to investigate the outcomes related to ERCP in relation to major papilla morphology. Methods: This study was performed prospectively on 581 patients undergoing ERCP. During ERCP, the endoscopist determined the morphology of the major papilla before the cannulation. Primary outcomes included overall operative success rate and post-ERCP pancreatitis (PEP) at 30 days. Secondary outcomes included clinically significant bleeding, perforation, cholangitis or sepsis, difficult cannulation, number of cannulation attempts, and duration of cannulation. Results: Papilla type 2 (OR=2.36, 95% CI: 1.07-5.20) and type 3b (OR=3.19, 95% CI: 1.16-8.73) were associated with decreased odds of procedure success. PEP was directly associated with type 4 papilla (OR=3.30, 95% CI: 1.21-8.98). There were direct correlation between difficult cannulation and types 3a (OR=1.89, 95% CI: 1.20-2.98) and 3b (OR=5.05, 95% CI: 1.98-12.86), cannulation duration more than 10 minutes and types 2 (OR=2.66, 95% CI: 1.31-5.39), 3a (OR=2.18, 95% CI:1.30-3.64), and 3b (OR=4.97, 95% CI: 1.94-12.71), and attempted cannulation more than 5 times and types 3a (OR=1.64, 95% CI: 1.01-2.69), and 3b (OR=4.40, 95% CI: 1.75-11.09). Conclusion: The findings of this study showed that ERCP failure is associated with types 2 and 3b papilla, and papilla type 4 is an independent risk factor for PEP.


  • Open Access

    Comparative Analysis of COVID‐19 Severity and Mortality Among Vaccinated and Unvaccinated Individuals During the Delta Variant Surge in a Tertiary Care Center: A Cohort Study

    by Fatemeh Hasani, Zahra Norouzi, Kimia Jazi, Gholamreza Roshandel, Alireza Norouzi

    Background and Aims: On March 11, 2020, the World Health Organization declared Coronavirus disease 2019 (COVID‐19) as a pandemic. The spread of the Delta variant of coronavirus started in June 2021 and accounted for the fifth peak of COVID‐19 in Iran in July 2021. According to reports from other countries, vaccination protects against severe diseases caused by COVID‐19, including the Delta variant. Studies have also shown that vaccination provides strong protection against SARS‐CoV‐2 infection, COVID‐19‐related hospitalization, and mortality. This retrospective cohort study was designed based on the medical care monitoring center database of Sayyad Shirazi Hospital. Methods: COVID‐19 confirmed patients' data were extracted for this study from June 22, 2021, to September 22, 2021 including demographic characteristics, signs and symptoms, ICU admission, need for aggressive oxygen therapy, including intubation, mortality, and vaccination status. Results: A total of 2962 patients were enrolled. Being vaccinated was associated with a 4.14‐fold increase in survival (adjusted OR = 4.14; 95% CI: 2.22–7.69; p < 0.01), and individuals in a younger age group demonstrated a 5.58‐fold higher likelihood of surviving (adjusted OR = 5.58; 95% CI: 4.25–8.14; p < 0.01). The risk of severe COVID‐19 was significantly lower in vaccinated individuals, showing a 3.12‐fold decrease in risk (adjusted OR = 3.12; 95% CI: 2.06–4.72; p < 0.01), and in younger age groups, the risk exhibited a 3.28‐fold decrease (adjusted OR = 3.28; 95% CI: 2.66–4.04; p < 0.01). Conclusion: The present results suggest that receiving at least one dose of COVID‐19 vaccine had a significant relationship with decreased COVID‐19 severity and mortality in vaccinated patients compared to unvaccinated patients.


  • Open Access

    Association of oral manifestations with severity of the disease in ulcerative colitis patients

    by Nikta Taghizadeh Tabarsi, Nazanin Mortazavi, Alireza Norouzi, Sima Besharat, Nasser Behnampour, Negar Asgari

    Inflammatory bowel diseases (IBD), such as Crohn’s disease (CD) and ulcerative colitis (UC), are chronic conditions primarily affecting the intestines. This study aims to identify the nature and frequency of oral symptoms and signs in patients with ulcerative colitis and to explore the connection between these complications and the activity of the disease. This descriptive-analytical study involved ulcerative colitis patients who visited the gastroenterology clinic at Shahid Sayad Shirazi Hospital in Gorgan, along with an equal number of healthy companions as a control group in 2019. A gastroenterology internist assessed the disease severity through clinical examination and a simple clinical disease activity index for colitis patients. The collected data were then analyzed statistically using SPSS version 19. The average age of patients in the case group was 41.84 ± 11.66 years, while in the control group it was 40.43 ± 12.67 years. There was a significant correlation between difficulty swallowing, burning sensation in the mouth, vomiting, acidic taste, the presence of oral ulcers, and a coated tongue with the severity of disease activity (p < 0.05). However, no significant relationship was found between other variables and the severity of disease activity (p > 0.05). The results of this study confirm that as the severity of ulcerative colitis increases, the occurrence of oral lesions also rises, particularly during severe disease activity. Among oral symptoms, dry mouth had the highest incidence, followed by bad breath and changes in taste. The most common oral lesions observed were a coated tongue, grooved tongue, and oral ulcers, respectively.


  • Open Access

    Clinical and Laboratory Manifestations of Patients with Liver Cirrhosis Infected with Coronavirus Disease

    by Mohanna Yusefi, Mohammadrafi Damirchi, Alireza Norouzi

    Background and Objective: The coronavirus disease 2019 (COVID-19) pandemic has posed a significant threat to both healthy individuals and those with chronic diseases, including liver cirrhosis. This study aimed to evaluate the clinical and laboratory manifestations and treatment outcomes of patients with liver cirrhosis who were infected with COVID-19. Methods: This ...

  • Open Access

    A Comparative Analysis of Norepinephrine with Midodrine/Octreotide in Patients with Hepatorenal Syndrome-acute Kidney Injury

    by Maryam Maghsudlou, Alireza Nourozi, Fatemeh Mehravar, Saeid Amirkhanlou

    Background: Hepatorenal Syndrome (HRS) is a severe complication of end-stage liver disease characterized by functional renal impairment. This study aimed to assess the efficacy of norepinephrine compared to midodrine/octreotide in managing patients diagnosed with hepatorenal syndrome type 1. Materials and Methods: In this double-blind Randomized Clinical Trial, 50 patients with hepatorenal syndrome type 1 were randomly assigned to the norepinephrine and midodrine/octreotide groups. The norepinephrine group received an initial dose of 1 mg/h (up to a maximum of 4 mg/h) along with daily intravenous injections of 20% albumin (20-40 grams per day) throughout the study period. The control group received midodrine (maximum dose of 15 mg three times a day), octreotide (maximum dose of 200 micrograms intravenously three times a day), and 20 to 40 mg of 20% albumin daily. The primary efficacy measure was the percentage of patients achieving a complete response, defined by the restoration of serum creatinine levels to within 0.3 mg/dl of the baseline by the end of treatment. Results: There was no significant difference in the rate of complete response between the norepinephrine group (7/25, 28%) and the midodrine/octreotide group (3/25, 12%) (p=0.15). The mortality rate was 10 (40%) in the norepinephrine group and 12 (48%) in the midodrine/octreotide group. Although the mortality rate was higher in the midodrine/octreotide group (12/25, 48%) compared to the norepinephrine group (10/25, 40%), this difference was not statistically significant (p=0.77). Conclusion: The study findings suggest that the norepinephrine treatment regimen can be as effective as or more effective than the midodrine/octreotide regimen in treating hepatorenal syndrome in cirrhotic patients. Therefore, these two treatment regimens can be used interchangeably. Clinical Trial Registration Number: IRCT20230228057568N1


  • Open Access

    Comparative Analysis of COVID-19 Severity and Mortality Among Vaccinated and Unvaccinated Individuals During the Delta Variant Surge in a Tertiary Care Center

    by Fatemeh Hasani, Zahra Norouzi, Gholamreza Roshandel, Alireza Norouzi

    Introduction: On March 11, 2020, the World Health Organization (WHO) declared Coronavirus disease 2019 (COVID-19) as a pandemic. The spread of the Delta variant of coronavirus started in June 2021 and accounted for the fifth peak of COVID-19 in Iran in July 2021. According to reports from other countries, vaccination protects against severe diseases caused by COVID-19, including the Delta variant. Studies have also shown that vaccination provides strong protection against SARS-CoV-2 infection, COVID-19-related hospitalization, and mortality. This retrospective cohort study was designed based on the medical care monitoring center (MCMC) database of Sayyad Shirazi Hospital.Methods: The following patient data were extracted for this study: demographic characteristics, signs and symptoms, ICU admission, need for aggressive oxygen therapy, including intubation, mortality, and vaccination status. Results: Being vaccinated was associated with a 4.14-fold increase in survival (adjusted OR=4.14; 95% CI: 2.22 to 7.69; PConclusion: The present results suggest that receiving at least one dose of COVID-19 vaccine had a significant relationship with decreased COVID-19 severity and mortality in vaccinated patients compared to unvaccinated patients.

  • Open Access

    Primary Biliary Tract Cancers in Golestan, Iran: 13-Year Experience of Golestan Population-Based Cancer Registry

    by Ali Ashkbari, Fazel Isapanah Amlashi, Sima Besharat, Mostafa Mofidi, Taghi Amiriani, Abdolreza Fazel, Mehdi Alimadadi, Faezeh Salamat, Seyyed Mehdi Sedaghat, Somayeh Livani, et al.

    Background: Epidemiological research on the high-risk population might be helpful in early detection and prevention of biliary tract malignancies. This study assesses the prevalence of biliary tract cancer (BTC) in the Golestan province, northeastern Iran, between 2004 and 2016. Methods: The current study used information from the Golestan Population-based Cancer Registry (GPCR) to access the epidemiology of BTC across a 13-year period while taking into account temporal and geographic differences. The number of cases, crude rates, age-standardized incidence rates (ASRs) per 100,000 person-years, average annual percent change (AAPC), age-specific incidence rates, and 95% confidence intervals (CI) were reported for each year with respect to gender and place of residence. Results: Totally, 224 instances of BTC overall (54% of whom were females) were reported throughout the research period. The ASR of BTC was 1.7 (95% CI: 1.4‒2) for females and 1.4 (95% CI: 1.1‒1.6) for men, respectively. Males exhibited a growing time trend in incidence (AAPC: 7.18; CI: 0.06‒14.81; P-value:0.048), whereas females had a decreasing trend (AAPC: 0.82; CI: -5.94‒4.57; P-value: 0.740). Both sexes saw an increase in age-specific incidence rates starting at the age of 45; however, males experienced a significant increase in incidence in the age group of 75 to 79 while the female rates grew steadily. Conclusion: The focus for cancer control in this region may be given to demographic groups with a combination of risk factors, including male gender, older age, and urban residence.

  • Open Access

    Prevalence of Abnormal Colonoscopic Findings in the Colorectal Cancer Screening Program with Fecal Immunochemical Test in Average Risk Individuals

    by Zahra Norouzi, Fatemeh Hasani, SeyyedMehdi Sedaghat, Hamideh Sadeghzadeh, Alireza Norouzi, Mehdi Alimadadi, Sima Besharat, Zoha Riyahi

    Background: The fecal immunochemical test (FIT) is a stool-based noninvasive test for colorectal cancer (CRC) screening. We aimed to evaluate the colonoscopy results in a population-based CRC screening of average-risk asymptomatic individuals with a positive FIT. Methods: We conducted a cross-sectional study involving 7947 individuals aged 50 to 69 years from 22 primary health care centers. Demographic data were extracted from the primary health care database called 'NAB.' All eligible participants were provided with FIT kits, and those with positive FIT results were referred for colonoscopy. We evaluated the pathologies identified during abnormal colonoscopies. Findings: Our study enrolled 7175 individuals with a mean (SD) age of 58.45 (5.45), of whom 4607 (64.2%) were female and 6226 (86.8%) were married. Out of the participants, 549 individuals tested positive for FIT, yielding a FIT positivity rate of 7.65%. The participation rate for colonoscopy was 55.56% (n=305), and among these, 87 patients had abnormal findings. Among all polyps, adenomas and hyperplastic polyps had higher rates compared to other types (49.48% and 21.64%, respectively). The majority of polyps were found in the rectum and sigmoid colon (73.3%). We observed that 11 patients had CRC based on colonoscopy findings. Abnormal colonoscopy findings were significantly higher in men (P < 0.001, OR=2.25) and in older patients (P=0.015, OR=1.57). Additionally, urban living was identified as a risk factor for colorectal pathologies (OR=2.30). Conclusion: Based on the data obtained in this study, FIT emerges as a suitable tool for colorectal cancer screening. Given its effectiveness in detecting precancerous lesions and CRCs, patients can greatly benefit from FIT for the prevention and early treatment of CRC. Furthermore, considering the higher incidence of abnormal colonoscopy findingsin men and older patients, CRC screening using FIT can significantly reduce the prevalence of colorectal neoplasia in these groups. Nevertheless, to comprehensively evaluate the quality of FIT tests for CRC screening in Iran, further studies with larger sample sizes are warranted.